<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01047254</url>
  </required_header>
  <id_info>
    <org_study_id>2007-005352-17</org_study_id>
    <nct_id>NCT01047254</nct_id>
  </id_info>
  <brief_title>Bupropion for the Treatment of Apathy in Alzheimer's Dementia</brief_title>
  <acronym>APA-AD</acronym>
  <official_title>A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Bupropion for the Treatment of Apathy in Alzheimer's Dementia(Apa-AD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Physician of neurology, psychiatry and psychotherapy Horn, MD; Bad Honnef</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universität Duisburg-Essen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Erlangen-Nürnberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Goettingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Saarland University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Philipps University Marburg Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rostock</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Apathy in dementia prevents successful application of non-pharmacological treatments,
      accelerates cognitive and functional decline and increases disease-related costs by earlier
      need for full-time care. Apathy is a distinct entity and occurs independently of other
      neuropsychiatric syndromes, like depression.

      Today, there is no high-level evidence for any effective treatment of apathy in AD. In
      contrast to other neuropsychiatric syndromes in AD, like psychosis and depression, and
      despite its high prevalence and clinical relevance, apathy has never been the primary outcome
      in a clinical trial. Basic and clinical research has provided a distinct model of the
      pathophysiology of apathy with dopamine and norepinephrine as the key neurotransmitter
      systems involved. The antidepressant Bupropion is a dopamine and norepinephrine reuptake
      inhibitor. There is evidence from case-series, that Bupropion reduces apathy in patients with
      organic brain disorders. This study will test the efficacy and safety of Bupropion in the
      treatment of apathy in AD in a 12-week multicenter doubleblind placebo controlled trial.
      Secondary endpoints will be quality of life of patients, caregivers' distress, ability of
      patients to perform activities of daily living,utilization of healthcare resources by
      patients and by caregivers, and cognitive functions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Apathy Evaluation Scale (AES) score</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>NPI total score;NPI caregivers' distress total score;ADCS-ADL; QoL-AD; RUD;ADAScog;MMSE</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Apathy in Dementia</condition>
  <arm_group>
    <arm_group_label>Bupropion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Buproprion 150-300 mg in a flexible dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elontril</intervention_name>
    <description>flexible dose of Bupropion 150-300 mg</description>
    <arm_group_label>Bupropion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild to moderate Alzheimer's dementia, male and female (NINCDS/ADRDA criteria)

          -  Presence of clinically relevant apathy defined by the Neuropsychiatric Inventory (NPI)
             apathy item (score of &gt;/= 4 points) and the Marin/Starkstein criteria for apathy

          -  MMSE: 10-25

          -  Outpatient status, not institutionalized

          -  Presence of reliable caregiver

          -  Stable treatment with antidementia drugs for at least three months prior to entry or
             no treatment with antidementia drugs

        Exclusion Criteria:

          -  Other Dementia (e.g. vascular dementia, Lewy-body dementia, fronto-temporal dementia)

          -  Presence of a clinically relevant depression defined by either the NPI depression item
             (score &gt;/= 4 points) or DSM-IV criteria for major depressive episode (with depressed
             mood)

          -  Alcoholism and Benzodiazepine addiction

          -  Current treatment with antipsychotics and antidepressants (including St. John's wart)

          -  Current treatment with dopaminergic agents or Amantadin

          -  Current treatment with benzodiazepines

          -  Current treatment with MAO inhibitor (Bupropion contraindication)

          -  Known sensibility to Bupropion treatment

          -  Severe psychiatric disease (including hospitalization) in the last 6 months, suicide
             attempt, acute psychotic symptoms

          -  Severe physical illness, that do not allow a participation in a 12-week period of
             treatment

          -  Medical history with seizures

          -  Medical history with tumors of the central nervous system

          -  Severe craniocerebral injury and medical history with cerebral substance defect

          -  Clinically relevant renal disease, liver insufficiency

          -  Simultaneous treatment, which reduces the seizure threshold (e.g. antipsychotics,
             antidepressants, antimalarial agents, Tramadol, Theophyllin, systemic steroids in
             higher dose, Chinolone, sedative antihistamines)

          -  Simultaneous treatment, which is metabolized through Cytochrom P450-Isoenzym 2D6 (e.g.
             these beta blockers: Metoprolol, Proanolol, Timolol, Carvediol, Nebivolol,
             Typ-1C-Antiarrhyhtmics for e.g. Propafenon, Flecinid) (except Donepezil and
             Galantamin)

          -  Simultaneous treatment with drugs, which may interfere with the metabolization of
             Bupropion (e.g. Carbamazepin, Phenytoin, Valproat, Ritonavir, Lopinavir)

          -  Diabetes mellitus, which is therapeutically poorly regulated and treated by medication

          -  Treatment with stimulants and appetite depressants

          -  Participation in other clinical trials with in the last 3 months

          -  Suicidal tendency

          -  Known lactose intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Jessen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Bonn</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry, University Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2010</study_first_submitted>
  <study_first_submitted_qc>January 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2010</study_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Frank Jessen</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

